How effective is the new drug cabozantinib in treating advanced renal cancer?

The new drug cabozantinib has shown significant efficacy in the treatment of advanced kidney cancer.

Cabotinib can target proteins related to the escape mechanism of cancer cells, such as tyrosine kinasesMET and AXL etc. This multi-target inhibitory effect allows cabozantinib to have a broader range of action when attacking cancer cells, thus improving the therapeutic effect.

It has been observed through clinical trials that cabozantinib can significantly reduce tumor volume in patients with advanced renal cancer. This finding suggests that cabozantinib has a positive effect in controlling tumor growth and helping to prolong patient survival.

In second-line treatment of kidney cancer, when the cancer cells have become resistant to first-line drugs, cabozantinib has shown greater efficacy than current standard treatments such as everolimus. This means cabozantinib could provide a new treatment option for patients who have developed resistance to other drugs.

Cabozantinib has also shown impressive results when used in combination with other drugs. For example, cabozantinib combined with PD-1 inhibitors such as nivolumab has shown excellent efficacy in the treatment of advanced renal cell carcinoma. This combination therapy can significantly improve patients' progression-free survival and overall survival while reducing the risk of disease progression.

The safety of cabozantinib has been verified in multiple clinical trials. Although patients may experience some adverse reactions, such as hypertension, diarrhea, etc., these reactions are usually controllable and can be alleviated through appropriate dose adjustment or supportive treatment.